Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.

Authors :: Gastinne T
Le Bourgeois A
Coste-Burel M
Guillaume T
Peterlin P
Garnier A
Imbert BM
Drumel T
Mahe B
Dubruille V
Blin N
Lok A
Touzeau C
Tessoulin B
Jullien M
Vanthygem S
Béné MC
Moreau P
Le Gouill S
Chevallier P
Source :: British journal of haematology [Br J Haematol] 2022 Jan; Vol. 196 (2), pp. 360-362. Date of Electronic Publication: 2021 Sep 02.
Publication Year :: 2022

Subjects :: Adult
Aged
Antigens, Viral immunology
Antineoplastic Combined Chemotherapy Protocols therapeutic use
BNT162 Vaccine adverse effects
Biological Products therapeutic use
Combined Modality Therapy
Female
Fever etiology
Hematopoietic Stem Cell Transplantation
Humans
Immunization, Secondary
Immunocompromised Host
Immunogenicity, Vaccine
Lymphoma, Non-Hodgkin immunology
Lymphoma, Non-Hodgkin therapy
Male
Middle Aged
Pain etiology
Precursor Cell Lymphoblastic Leukemia-Lymphoma immunology
Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
Receptors, Antigen, T-Cell therapeutic use
Receptors, Chimeric Antigen therapeutic use
Spike Glycoprotein, Coronavirus immunology
Vaccination
Young Adult
Antibodies, Viral biosynthesis
BNT162 Vaccine immunology
COVID-19 prevention & control
Immunoglobulin G biosynthesis
Immunotherapy, Adoptive
SARS-CoV-2 immunology

Full Text Access

Tools